RESUMEN
Rheumatoid arthritis is a chronic disease that results in a disabling and painful condition as it progresses to destruction of the articular cartilage and ankylosis of the joints. Although the cause of the disease is still unknown, evidence argues that autoimmunity plays an important part. There are increasing but contradictory views regarding serotonin being associated with activation of immunoinflammatory pathways and the onset of autoimmune reactions. We studied serotonin's involvement during collagen-induced arthritis in wild-type and Tph1(-/-) mice, which have markedly reduced peripheral serotonin levels. In wild-type mice, induction of arthritis triggered a robust increase in serotonin content in the paws combined with less inflammation. In Tph1(-/-) mice with arthritis, a marked increase in the clinical and pathologic arthritis scores was noticed. Specifically, in Tph1(-/-) mice with arthritis, a significant increase in osteoclast differentiation and bone resorption was observed with an increase in IL-17 levels in the paws and in Th17 lymphocytes in the draining lymph nodes, whereas T-regulatory cells were dampened. Ex vivo serotonin and agonists of the 5-HT2A and 5-HT2B receptors restored IL-17 secretion from splenocytes and Th17 cell differentiation in Tph1(-/-) mice. These findings indicate that serotonin plays a fundamental role in arthritis through the regulation of the Th17/T-regulatory cell balance and osteoclastogenesis.
Asunto(s)
Artritis Experimental/patología , Enfermedades Autoinmunes/inmunología , Resorción Ósea/patología , Serotonina/metabolismo , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Animales , Artritis Experimental/inmunología , Enfermedades Autoinmunes/patología , Resorción Ósea/inmunología , Diferenciación Celular , Modelos Animales de Enfermedad , Ratones Noqueados , Serotonina/inmunologíaRESUMEN
OBJECTIVE: Rheumatoid arthritis (RA) is an autoimmune joint disease associated with chronic inflammation of the synovium that causes profound damage of joints. Inflammation results in part from the influx of immune cells secreting inflammatory cytokines and the reduction in the number of Treg cells. We undertook this study to assess the effect of furin, a proteinase implicated in the proteolytic activity of various precursor proteins and involved in the regulation of both proteinase maturation and immune cells, in an experimental model of RA. METHODS: The effect of furin and its inhibitor α1-PDX was tested in mice with collagen-induced arthritis (CIA). Joints were processed for histology and protein expression. Levels of cytokines were measured in joint tissue, and Treg cell numbers were measured in spleens. RESULTS: Furin expression and activity were high in the synovial pannus in RA patients and mice with CIA. Systemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor α1-PDX, which enhanced these parameters. By preventing the development of synovial pannus, furin reduced the expression of metalloproteinases in the joints. In contrast, α1-PDX enhanced synovial proliferation and the expression and activity of matrix metalloproteinases. Furthermore, furin reversed the local Th1/Th2 balance and restored the number of Treg cells in the spleen, indicating mediation by immune cells. CONCLUSION: These findings show the protective role of exogenous furin against RA, mediated by an immune response. The data suggest the potential therapeutic use of furin or its derivatives in autoimmune diseases including RA.
Asunto(s)
Artritis Experimental/inmunología , Furina/farmacología , Articulaciones/efectos de los fármacos , Fiebre Reumática/inmunología , Animales , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/patología , Citocinas/metabolismo , Furina/uso terapéutico , Humanos , Articulaciones/metabolismo , Articulaciones/patología , Masculino , Ratones , Ratones Endogámicos DBA , Fiebre Reumática/tratamiento farmacológico , Fiebre Reumática/patología , Membrana Sinovial/efectos de los fármacos , Membrana Sinovial/metabolismo , Membrana Sinovial/patología , alfa 1-Antitripsina/farmacologíaRESUMEN
BACKGROUND: Osteoarthritis (OA) is characterised by cartilage degradation and bone lesions. Subchondral bone may be involved in the pathogenesis of cartilage matrix breakdown. OBJECTIVE: To assess the role of bone remodelling in OA by studying the effect of bisphosphonate on OA development in mice with high bone remodelling. METHODS: Mice overexpressing Runx2 (Runx2-Tg) under the control of collagen type I that displayed high bone remodelling were used. Joint instability was performed by partial medial meniscectomy to induce OA. RESULTS: Six weeks after surgery, tibial cartilage of Runx2-Tg mice displayed an increased number of ADAMTS-4- and ADAMTS-5-expressing chondrocytes compared with controls (p<0.05). This increase was higher in Runx2-Tg mice than in wild-type mice, although their OA score did not differ (2.5+/-0.6 vs 2.4+/-0.2, P=NS). Pamidronate reduced the OA score in Runx2-Tg mice but not in wild-type littermates (1.2+/-0.5 vs 2.7+/-0.4; p<0.05) despite the reduction of bone resorption and of the expression of cartilage proteases in both genotypes. CONCLUSIONS: These findings support the hypothesis that the level of bone resorption influences cartilage metabolism and that inhibition might prevent the progression of OA. Targeting bone resorption might therefore provide an approach to the treatment of high bone resorbing forms of OA.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Conservadores de la Densidad Ósea/uso terapéutico , Remodelación Ósea/efectos de los fármacos , Resorción Ósea/prevención & control , Osteoartritis/tratamiento farmacológico , Proteínas ADAM/metabolismo , Animales , Artritis Experimental/etiología , Artritis Experimental/metabolismo , Artritis Experimental/fisiopatología , Conservadores de la Densidad Ósea/farmacología , Remodelación Ósea/fisiología , Resorción Ósea/complicaciones , Resorción Ósea/metabolismo , Resorción Ósea/fisiopatología , Subunidad alfa 1 del Factor de Unión al Sitio Principal/biosíntesis , Difosfonatos/farmacología , Difosfonatos/uso terapéutico , Progresión de la Enfermedad , Evaluación Preclínica de Medicamentos , Epífisis/efectos de los fármacos , Epífisis/fisiopatología , Masculino , Meniscos Tibiales/cirugía , Ratones , Ratones Transgénicos , Osteoartritis/etiología , Osteoartritis/metabolismo , Osteoartritis/fisiopatología , Pamidronato , Proteoglicanos/metabolismoRESUMEN
Chondrocyte apoptosis may have a pivotal role in the development of osteoarthritis. Interest has increased in the use of anti-apoptotic compounds to protect against osteoarthritis development. In this work, we investigated the effect of adrenomedullin (AM), a 52 amino-acid hormone peptide, and a 31 amino-acid truncated form, AM(22-52), on chondrocyte apoptosis. Bovine articular chondrocytes (BACs) were cultured under hypoxic conditions to mimic cartilage environment and then treated with Fas ligand (Fas-L) to induce apoptosis. The expression of AM and its calcitonin receptor-like receptor (CLR)/receptor activity-modifying protein (RAMP) (receptor/co-receptor) was assessed by immunostaining. We evaluated the effect of AM and AM(22-52) on Fas-L-induced chondrocyte apoptosis. FAS expression was appreciated by RT-qPCR and immunostainings. The expression of hypoxia-inducible factor 1α (HIF-1α), CLR and one co-receptor (RAMP2) was evidenced. With BACs under hypoxia, cyclic adenosine monophosphate production increased dose-dependently with AM stimulation. AM significantly decreased caspase-3 activity (mean 35% decrease; p = 0.03) as a marker of Fas-L-induced apoptosis. Articular chondrocytes treated with AM showed significantly reduced cell death, along with downregulated Fas expression and production, as compared with AM(22-52). AM decreased articular chondrocyte apoptosis by downregulating a Fas receptor. These findings may pave the way for novel therapeutic approaches in osteoarthritis.
Asunto(s)
Adrenomedulina/farmacología , Apoptosis/efectos de los fármacos , Condrocitos/efectos de los fármacos , Proteína Ligando Fas/farmacología , Fragmentos de Péptidos/farmacología , Adrenomedulina/metabolismo , Animales , Proteína Similar al Receptor de Calcitonina/metabolismo , Cartílago Articular/metabolismo , Bovinos , Condrocitos/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Proteína 2 Modificadora de la Actividad de Receptores/metabolismo , Transducción de Señal/efectos de los fármacos , Receptor fas/metabolismoRESUMEN
Cartilage loss in osteoarthritis (OA) results from altered local production of growth factors and metalloproteases (MMPs). Furin, an enzyme involved in the protein maturation of MMPs, might regulate chondrocyte function. Here, we tested the effect of furin on chondrocyte catabolism and the development of OA. In primary chondrocytes, furin reduced the expression of MMP-13, which was reversed by treatment with the furin inhibitor α1-PDX. Furin also promoted the activation of Smad3 signaling, whereas activin receptor-like kinase 5 (ALK5) knockdown mitigated the effects of furin on MMP-13 expression. Mice underwent destabilization of the medial meniscus (DMM) to induce OA, then received furin (1 U/mice), α1-PDX (14 µg/mice) or vehicle. In mice with DMM, the OA score was lower with furin than vehicle treatment (6.42 ± 0.75 vs 9.16 ± 0.6, p < 0.01), and the number of MMP-13(+) chondrocytes was lower (4.96 ± 0.60% vs 20.96 ± 8.49%, p < 0.05). Moreover, furin prevented the increase in ALK1/ALK5 ratio in cartilage induced by OA. Conversely, α1-PDX had no effect on OA cartilage structure. These results support a protective role for furin in OA by maintaining ALK5 receptor levels and reducing MMP-13 expression. Therefore, furin might be a potential target mediating the development of OA.
Asunto(s)
Furina/farmacología , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Osteoartritis/prevención & control , Factor de Crecimiento Transformador beta/farmacología , Receptores de Activinas Tipo I/análisis , Receptores de Activinas Tipo I/efectos de los fármacos , Receptores de Activinas Tipo II , Animales , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Ratones , Osteoartritis/tratamiento farmacológico , Proproteína Convertasas/farmacología , Receptor Tipo I de Factor de Crecimiento Transformador beta/efectos de los fármacosRESUMEN
INTRODUCTION: Sclerostin is a Wnt inhibitor produced by osteocytes that regulates bone formation. Because bone tissue contributes to the development of osteoarthritis (OA), we investigated the role of sclerostin in bone and cartilage in a joint instability model in mice. METHODS: Ten-week-old SOST-knockout (SOST-KO) and wild-type (WT) mice underwent destabilization of the medial meniscus (DMM). We measured bone volume at the medial femoral condyle and osteophyte volume and determined the OA score and expression of matrix proteins. Primary murine chondrocytes were cultured with Wnt3a and sclerostin to assess the expression of matrix proteins, proteoglycan release and glycosaminoglycan accumulation. RESULTS: Sclerostin was expressed in calcified cartilage of WT mice with OA. In SOST-KO mice, cartilage was preserved despite high bone volume. However, SOST-KO mice with DMM had a high OA score, with increased expression of aggrecanases and type X collagen. Moreover, SOST-KO mice with OA showed disrupted anabolic-catabolic balance and cartilage damage. In primary chondrocytes, sclerostin addition abolished Wnt3a-increased expression of a disintegrin and metalloproteinase with thrombospondin motifs, matrix metalloproteinases and type X collagen by inhibiting the canonical Wnt pathway. Moreover, sclerostin inhibited Wnt-phosphorylated c-Jun N-terminal kinase (JNK) and rescued the expression of anabolic genes. Furthermore, sclerostin treatment inhibited both Wnt canonical and non-canonical JNK pathways in chondrocytes, thus preserving metabolism. CONCLUSION: Sclerostin may play an important role in maintaining cartilage integrity in OA.
Asunto(s)
Glicoproteínas/fisiología , Osteoartritis de la Rodilla/metabolismo , Vía de Señalización Wnt/fisiología , beta Catenina/fisiología , Proteínas Adaptadoras Transductoras de Señales , Animales , Western Blotting , Cartílago Articular/metabolismo , Condrocitos/citología , Condrocitos/efectos de los fármacos , Colágeno Tipo X/metabolismo , Desintegrinas/metabolismo , Glicoproteínas/farmacología , Péptidos y Proteínas de Señalización Intercelular , Inestabilidad de la Articulación/metabolismo , Masculino , Metaloproteasas/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Osteoartritis de la Rodilla/patología , Reacción en Cadena de la Polimerasa , Proteína Wnt3A/farmacologíaRESUMEN
OBJECTIVE: Subchondral bone modifications occur early in the development of osteoarthritis (OA). The level of bone resorption might impact cartilage remodeling. We therefore assessed the in vivo and in vitro effects of targeting bone resorption in OA and cartilage metabolism. METHODS: OA was induced by meniscectomy (MNX) in ovariectomized osteopenic mice (OP) treated with estradiol (E2), pamidronate (PAM), or phosphate buffered saline (PBS) for 6 weeks. We assessed the subchondral bone and cartilage structure and the expression of cartilage matrix proteases. To assess the involvement of bone soluble factors in cartilage metabolism, supernatant of human bone explants pre-treated with E2 or PAM were transferred to cartilage explants to assess proteoglycan release and aggrecan cleavage. OPG/RANKL mRNA expression was assessed in bone explants by real-time quantitative PCR. The role of osteoprotegerin (OPG) in the bone-cartilage crosstalk was tested using an OPG neutralizing antibody. RESULTS: Bone mineral density of OP mice and osteoclast number were restored by E2 and PAM (p<0.05). In OP mice, E2 and PAM decreased ADAMTS-4 and -5 expression, while only PAM markedly reduced OA compared to PBS (2.0±0.63 vs 5.2±0.95; p<0.05). OPG/RANKL mRNA was increased in human bone explants treated with both drugs (2.2-3.7-fold). Moreover, supernatants from bone explants cultured with E2 or PAM reduced aggrecan cleavage and cartilage proteoglycan release (73±8.0% and 80±22% of control, respectively, p<0.05). This effect was reversed with osteoprotegerin blockade. CONCLUSION: The inhibition of bone resorption by pamidronate in osteopenic mice alleviates the histological OA score with a reduction in the expression of aggrecanases. Bone soluble factors, such as osteoprotegerin, impact the cartilage response to catabolic factors. This study further highlights the importance of subchondral bone in the regulation of joint cartilage damage in OA.